Angela Volkert

685 total citations
16 papers, 480 citations indexed

About

Angela Volkert is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Angela Volkert has authored 16 papers receiving a total of 480 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Hematology, 6 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in Angela Volkert's work include Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). Angela Volkert is often cited by papers focused on Acute Myeloid Leukemia Research (9 papers), Chronic Myeloid Leukemia Treatments (5 papers) and Lymphoma Diagnosis and Treatment (4 papers). Angela Volkert collaborates with scholars based in United States, France and Japan. Angela Volkert's co-authors include Jörge E. Cortes, Tim H. Brümmendorf, Hagop M. Kantarjian, Carlo Gambacorti‐Passerini, Nadine Besson, Eric Leip, Anna Turkina, Steven Arkin, Richat Abbas and H. Jean Khoury and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Angela Volkert

14 papers receiving 473 citations

Peers

Angela Volkert

HEMAT

GENET

RHEUM

ONCOL

J. Janssen Netherlands

Patricia Martin‐Regueira United States

А К Голенков Russia

Bruno Villemagne France

Alessandra Gnani Italy

Simona Bassi Italy

Simona Luatti Italy

Sara Dellasala United States

Nils Hansen Sweden

Mei-Li Wen United States

J. Janssen Netherlands

Angela Volkert

285 ×0.8

HEMAT

222 ×0.7

GENET

111 ×0.7

RHEUM

70 ×0.6

ONCOL

75 ×1.1

Citations per year, relative to Angela Volkert Angela Volkert (= 1×) peers J. Janssen

Countries citing papers authored by Angela Volkert

Since Specialization

Citations

This map shows the geographic impact of Angela Volkert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Angela Volkert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Angela Volkert more than expected).

Fields of papers citing papers by Angela Volkert

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Angela Volkert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Angela Volkert. The network helps show where Angela Volkert may publish in the future.

Co-authorship network of co-authors of Angela Volkert

This figure shows the co-authorship network connecting the top 25 collaborators of Angela Volkert. A scholar is included among the top collaborators of Angela Volkert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Angela Volkert. Angela Volkert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Stein, Eytan M., Stéphane de Botton, Thomas Cluzeau, et al.. (2023). Use of tamibarotene, a potent and selective RARα agonist, in combination with azacitidine in patients with relapsed and refractory AML with RARA gene overexpression. Leukemia & lymphoma. 64(12). 1992–2001. 2 indexed citations

DeZern, Amy E., Pierre Fenaux, Dries Deeren, et al.. (2022). MDS-110 SELECT-MDS-1 Trial in Progress: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Tamibarotene/Azacitidine Versus Placebo/Azacitidine in Newly Diagnosed Adult Patients Selected for RARA-Positive Higher-Risk MDS. Clinical Lymphoma Myeloma & Leukemia. 22. S303–S304.

Kambhampati, Suman, Christine M. McMahon, Daniel A. Pollyea, et al.. (2022). Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy. Blood. 140(Supplement 1). 3333–3335. 2 indexed citations

DeZern, Amy E., Giovanni Marconi, Dries Deeren, et al.. (2022). A randomized, double-blind, placebo-controlled study of tamibarotene/azacitidine versus placebo/azacitidine in newly diagnosed adult patients selected for RARA+ HR-MDS (SELECT-MDS-1).. Journal of Clinical Oncology. 40(16_suppl). TPS7075–TPS7075. 2 indexed citations

Stein, Eytan M., Stéphane de Botton, Thomas Cluzeau, et al.. (2020). Initial Results from a Biomarker-Directed Phase 2 Trial of SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia. Blood. 136(Supplement 1). 6–7. 2 indexed citations

Papadopoulos, Kyriakos P., Manish Sharma, Erika Hamilton, et al.. (2020). First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). TPS3662–TPS3662. 5 indexed citations

Botton, Stéphane de, Thomas Cluzeau, Carlos E. Vigil, et al.. (2020). SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia. Blood. 136(Supplement 1). 4–5. 6 indexed citations

Fiore, Christopher, Michael Kelly, Angela Volkert, et al.. (2020). Selection of RARA-Positive Newly Diagnosed Unfit AML Patients with Elevated RARA Gene Expression Enriches for Features Associated with Primary Resistance to Venetoclax and Clinical Response to SY-1425, a Potent and Selective RARα Agonist, Plus Azacitidine. Blood. 136(Supplement 1). 15–16.

Cook, Rachel J., Tamara K. Moyo, Jane L. Liesveld, et al.. (2018). Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Combination with Azacitidine or Daratumumab in Non-APL Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood. 132(Supplement 1). 2735–2735. 4 indexed citations

10.

Goy, André, Andres Forero, Nina D. Wagner‐Johnston, et al.. (2016). A phase 2 study of inotuzumab ozogamicin in patients with indolent B‐cell non‐Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. British Journal of Haematology. 174(4). 571–581. 40 indexed citations

11.

Sangha, Randeep, Andrew Davies, Nam H. Dang, et al.. (2013). Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL). Blood. 122(21). 1821–1821. 2 indexed citations

12.

DeAngelo, Daniel J., Wendy Stock, Stephen H. Petersdorf, et al.. (2012). Weekly Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory CD22-Positive Acute Lymphoblastic Leukemia.. Blood. 120(21). 2612–2612. 6 indexed citations

13.

Luu, Kenneth T., Erik Vandendries, Angela Volkert, et al.. (2012). Abstract 3776: Antitumor response to inotuzumab ozogamicin (INO) in patients with refractory or relapsed indolent B-cell non-Hodgkin's lymphomas (NHL): Pharmacokinetic-pharmacodynamic (PK-PD) modeling and interim results from a phase II study. Cancer Research. 72(8_Supplement). 3776–3776. 2 indexed citations

14.

Cortes, Jörge E., Hagop M. Kantarjian, Tim H. Brümmendorf, et al.. (2011). Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 118(17). 4567–4576. 348 indexed citations

15.

Goy, André, Joseph W. Leach, W. Christopher Ehmann, et al.. (2010). Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial. Blood. 116(21). 430–430. 17 indexed citations

16.

Cortes, Jörge E., Hagop M. Kantarjian, Michele Baccarani, et al.. (2006). A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib.. Blood. 108(11). 168–168. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact